MCM
TXG icon

MAI Capital Management’s 10x Genomics TXG Stock Holding History

MAI Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65
Closed -$1.38K – 4542
2026
Q1 		$1.38K Buy
65
+41
+171% +$820 ﹤0.01% 4065
2025
Q4 		$392 Sell
24
-63
-72% -$952 ﹤0.01% 3897
2025
Q3 		$1.02K Sell
87
-412
-83% -$5.37K ﹤0.01% 3495
2025
Q2 		$5.78K Buy
499
+436
+692% +$3.97K ﹤0.01% 2991
2025
Q1 		$550 Hold
63
– – ﹤0.01% 3224
2024
Q4 		$905 Buy
+63
New +$994 ﹤0.01% 3212

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's TXG Position: Q2 2026 in Review

MAI Capital Management sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 65 shares — an estimated $1.38K sold.

MAI Capital Management first reported a position in TXG in Q4 2024 and held it in 6 quarters. The position peaked at $5.78K in Q2 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • MAI Capital Management reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 65 10x Genomics shares in Q2 2026, an estimated $1.38K.
  • MAI Capital Management first reported a position in 10x Genomics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's 10x Genomics position peaked at $5.78K in Q2 2025.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.